Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF)
Journal of Pre-Clinical and Clinical Research · 25.09.2025 · 19 (3) · 125-129
DOI: 10.26444/jpccr/209891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pre-Clinical and Clinical Research, online erschienen am 02.09.2025. Verfasst von Martyna Dutka und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Dutka, M., Mielnicka, N., Bernacki, P. P., Byczek, K., Wołkanowski, J., & Smycz, K. (2025). Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF). Journal of Pre-Clinical and Clinical Research, 19(3), 125-129. https://doi.org/10.26444/jpccr/209891
Vancouver
Dutka M, Mielnicka N, Bernacki PP, Byczek K, Wołkanowski J, Smycz K. Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF). Journal of Pre-Clinical and Clinical Research. 2025;19(3):125-129. doi:10.26444/jpccr/209891
BibTeX
@article{Dutka2025,
author = {Dutka, Martyna and Mielnicka, Natalia and Bernacki, Piotr Paweł and Byczek, Kacper and Wołkanowski, Juliusz and Smycz, Karol},
title = {Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF)},
journal = {Journal of Pre-Clinical and Clinical Research},
year = {2025},
volume = {19},
number = {3},
pages = {125--129},
doi = {10.26444/jpccr/209891}
}
EUVIMED